211 related articles for article (PubMed ID: 30450575)
21. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.
Escherich G; Zur Stadt U; Zimmermann M; Horstmann MA;
Br J Haematol; 2013 Oct; 163(2):240-7. PubMed ID: 23937310
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
23. HLA alleles associated with asparaginase hypersensitivity in Chinese children.
Chua GT; Rosa Duque JS; Cheuk DKL; Leung AWK; Wong WHS; Liu APY; Lee PPW; Ha SY; Chiang AKS; Ho MHK; Chu WK; Chan YS; Luk CW; Ling ASC; Kwan MYW; Yiu OKF; Wong ICK; Lau YL; Li CK; Leung WH; Chan GCF; Ip P; Kwok J
J Hematol Oncol; 2021 Oct; 14(1):182. PubMed ID: 34717720
[TBL] [Abstract][Full Text] [Related]
24. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study.
Lynggaard LS; Rank CU; Hansen SN; Gottschalk Højfeldt S; Henriksen LT; Jarvis KB; Ranta S; Niinimäki R; Harila-Saari A; Wolthers BO; Frandsen TL; Heyman M; Schmiegelow K; Albertsen BK
Blood Adv; 2022 Jan; 6(1):138-147. PubMed ID: 34625787
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.
Rajić V; Debeljak M; Goričar K; Jazbec J
Leuk Lymphoma; 2015; 56(11):3103-8. PubMed ID: 25697915
[TBL] [Abstract][Full Text] [Related]
26. Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
Rank CU; Wolthers BO; Grell K; Albertsen BK; Frandsen TL; Overgaard UM; Toft N; Nielsen OJ; Wehner PS; Harila-Saari A; Heyman MM; Malmros J; Abrahamsson J; Norén-Nyström U; Tomaszewska-Toporska B; Lund B; Jarvis KB; Quist-Paulsen P; Vaitkevičienė GE; Griškevičius L; Taskinen M; Wartiovaara-Kautto U; Lepik K; Punab M; Jónsson ÓG; Schmiegelow K
J Clin Oncol; 2020 Jan; 38(2):145-154. PubMed ID: 31770057
[TBL] [Abstract][Full Text] [Related]
27. Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.
Kutszegi N; Semsei ÁF; Gézsi A; Sági JC; Nagy V; Csordás K; Jakab Z; Lautner-Csorba O; Gábor KM; Kovács GT; Erdélyi DJ; Szalai C
PLoS One; 2015; 10(10):e0140136. PubMed ID: 26457809
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
Cooperation Group of Phase II Clinical Trial of PEG-Asp
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
[TBL] [Abstract][Full Text] [Related]
29. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
30. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
31. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
33. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
34. Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Kondyli M; Tremblay DÉ; Rezgui A; Serfaty SA; Gagné V; Ribère M; Laverdière C; Leclerc JM; Tran TH; Sinnett D; Krajinovic M
Leuk Res; 2021 Oct; 109():106650. PubMed ID: 34198115
[No Abstract] [Full Text] [Related]
35. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries.
Albertsen BK; Schrøder H; Jakobsen P; Müller HJ; Carlsen NT; Schmiegelow K
Br J Clin Pharmacol; 2001 Oct; 52(4):433-7. PubMed ID: 11678787
[TBL] [Abstract][Full Text] [Related]
36. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
37. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
[TBL] [Abstract][Full Text] [Related]
38. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
39. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
40. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]